Scientists from the German Cancer Research Center and the Universities of Cambridge and Edinburgh have been studying the evolution of tumors following chemical damage. They discovered that the DNA lesions caused by the chemical are not eliminated immediately, but are passed on unrepaired over several rounds of cell division. Both DNA strands with their independent sets of lesions are separated during cell division, resulting in two daughter cells with different patterns of DNA changes - their mutation profiles. During further rounds of replication, the lesions repeatedly generated new combinations of mutations, providing many chances to find the best combination for tumor growth. This "lesion segregation" can drive unexpectedly complex patterns of mutations in the tumor genome, as the scientists have now published in the journal Nature.
Tobacco smoke, many chemicals or the UV radiation of sunlight: Numerous environmental and lifestyle factors damage the genetic material of our cells and can thus trigger cancer. These factors modify individual DNA building blocks, called nucleotides, in such a way that they are no longer correctly recognized when the DNA is duplicated. The consequence: False "counterparts" are incorporated into the newly synthesized DNA strand.
Cells have a variety of repair systems that can remove and replace such defective nucleotides. But which defects are repaired and which escape repair and can lead to cancer-promoting mutations? What effect does this have on the mutation pattern of tumor cells? And how do these mutations spread during the clonal expansion of individual cells during tumorigenesis?
Answering these questions was the goal of a collaboration among the laboratories of Duncan Odom at the German Cancer Research Center (DKFZ) and the University of Cambridge's Cancer Research UK - Cambridge Institute, Martin Taylor and Colin Semple at the University of Edinburgh's MRC Human Genetics Unit, as well as Paul Flicek at EMBL EBI and Professor Nuria Lopez-Bigas at IRB Barcelona. These researchers used the DNA-damaging chemical diethylnitrosamine to induce hundreds of liver tumors in mice and analyzed the genomes of these cancers. On average, this chemical mutagen caused about 60,000 point mutations in the genome of each cancer cell.
To their surprise, the scientists discovered during the analysis of the mutation signatures that the lesions caused by the chemical remains largely unrepaired over several cell generations. The two DNA strands, which were damaged independently of each other, are separated during cell division. The two resulting daughter cells then develop two different mutation profiles. The researchers refer to this as "lesion segregation".
During further replication rounds, the lesions repeatedly lead to new, different mutations, since four different DNA nucleotides can be incorporated at the defective site. Cancer cells are usually exposed to several mutagenic events, so that this cycle of DNA damage and lesion segregation repeats over time, ultimately resulting in extremely complex patterns of mutations in cancers.
The mutations affect important genes known as cancer drivers. In their study, the scientists found defects in genes of the cancer-promoting BRAF, RAS and RAF signaling pathways. "In the end, those cancer cells that carry the most favorable pattern of mutations will prevail. They can grow the fastest, escape the immune system and possibly survive therapies better," says lead author Sarah Aitken, a Cambridge-based clinician-scientist.
"Persistent DNA lesions induced by chemotherapeutic agents also segregate and produce several generations of further mutations. We need to be aware of this therapeutically, and in future drug development," said Martin Taylor from University of Edinburgh's MRC Human Genetics Unit.
"Thanks to the concept of lesion segregation, we now understand better how the surprising complexity of mutations in cancer cells can arise," summarizes Duncan Odom. "This may help explain how cancer cells can react so flexibly to survival challenges, which in turn helps them to quickly develop resistance to drugs or adapt to foreign tissue environments."
This project was supported by a strategic sequencing award and Institutional core-funding from Cancer Research UK, as well as grants from the European Research Council, Helmholtz Society, and from UKRI/Medical Research Council.
Sarah J. Aitken, Craig J. Anderson, Frances Connor, Oriol Pich, Vasavi Sundaram, Christine Feig, Tim F. Rayner, Margus Lukk, Stuart Aitken, Juliet Luft , Elissavet Kentepozidou, Claudia Arnedo-Pac, Sjoerd Beentjes, Susan E. Davies, Ruben M. Drews, Ailith Ewing, Vera B. Kaiser, Ava Khamseh, Erika López-Arribillaga, Aisling M. Redmond, Javier Santoyo-Lopez, Inés Sentís, Lana Talmane, Andrew D. Yates, Colin A. Semple, Núria López-Bigas, Paul Flicek, Duncan T. Odom, Martin S. Taylor: Pervasive lesion segregation shapes cancer genome evolution.
Nature 2020, DOI: 10.1038/s41586-020-2435-1
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.
Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Tumour Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.